| Autor: |
Yue Zeng, Xing-Xiang Pu, Feng-Jiao He, Chun-Hong Hu, Hong Zhu, Yan Huang, Yu-Rong Peng, Ji-An Zou, Jun-Qi Liu, Sheng-Hao Shi, Yue-Fei Liu, Fang Ma, Chao Deng, Zhen-Hua Qiu, Yan-Long Li, Ying-Zhe Zhang, Kun Huang, Xian-Ling Liu, Fang Wu |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
iScience, Vol 27, Iss 7, Pp 110219- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2589-0042 |
| DOI: |
10.1016/j.isci.2024.110219 |
| Popis: |
Summary: The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; p = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; p = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17.2 months; p = 0.044), and a higher 2-year LRFS rate (86.8% vs. 61.9%; p = 0.012). In EGFR mutant patients, PORT was not significantly correlated with improved survival outcomes. EGFR wild-type may a biomarker to identify the cohort that benefits from PORT. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
